Despite significant improvements in outcomes after liver transplantation (LT), organ rejection remains a common complication. Up to 30% of recipients will experience an episode of acute rejection within the first 12 months.^[@R1],[@R2]^ Furthermore, the occurrence of acute rejection may have significant impact on both mortality and morbidity.^[@R1]^

Contemporary diagnosis of acute rejection is based on the clinician's acumen in assessing the constellation of clinical signs and investigations. However, many of the investigations including serum liver biochemistry and radiological imaging are not specific for acute rejection.^[@R3],[@R4]^ Pathological states such as cholestasis, infection, and vascular thrombosis can also result in abnormalities for the above investigations. Liver biopsies are thus performed to establish a definitive diagnosis. However, liver biopsies are invasive and associated with the risks of pain, bleeding, and bile leak, as well as sampling issues.^[@R5],[@R6]^

Reliable, rapidly performed, minimally invasive methods in diagnosing acute rejection will improve the surveillance of graft health. The measurement of cytokines, chemokines, and small molecules has been described, but all of these have varying degrees of specificity for acute rejection. As such, these tests have not gained widespread adoption by clinicians.^[@R7],[@R8]^

Following solid-organ transplantation, cellular turnover in the donor organ continuously sheds cell-free DNA into the recipient circulation as donor-specific cell-free DNA (dscfDNA).^[@R9]^ Cellular injury during episodes of acute rejection increases dscfDNA levels in the recipient circulation, a consistent finding of previous dscfDNA studies in heart,^[@R10]^ lung,^[@R11]^ kidney,^[@R12]^ and liver^[@R13]^ transplantation. As an emergent biomarker, dscfDNA may thus address the clinical need for a rapid blood test to diagnose acute rejection after transplantation.

Detecting dscfDNA relies on identifying genetic differences between the donor and recipient. The use of the Y chromosome to distinguish donor-specific DNA from recipient-specific DNA limits the detection of donor-specific DNA in female recipients who are transplanted with male donor organs.^[@R9],[@R14]-[@R16]^

Normal genetic variants, such as single-nucleotide polymorphisms, deletion/insertion polymorphisms (DIP), and structural variations,^[@R17],[@R18]^ are potential donor-specific markers. The use of a panel of such polymorphisms chosen for high heterozygosity enables the differentiation of donor-specific DNA from recipient-specific DNA of all transplant recipients (except genetically identical twins).^[@R19]-[@R27]^

Modern techniques for measuring dscfDNA mostly utilize next-generation sequencing (NGS) or droplet digital PCR (ddPCR) platforms.^[@R28]^ The analysis of cell-free DNA by ddPCR is superior compared with conventional PCR platforms.^[@R29]^ Most importantly, the straightforward ddPCR workflow can be rapidly completed.^[@R25]^ NGS workflows, on the other hand, are expensive and require complex sample handling steps for library preparation and sequencing. Results from NGS can take between 3 and 28 days to turn around.^[@R20]-[@R22]^

We previously reported a DIP-based probe-free ddPCR methodology to measure dscfDNA that circumvented many of the described limitations.^[@R25]^ Allelic breakpoints of DIPs were exploited for amplification specificity using primers that hybridized across the breakpoints. Unlike prior ddPCR methodologies,^[@R13],[@R23],[@R30]^ our methodology harnessed the reproducibility and precision of ddPCR without the need for fluorescent probes to detect dscfDNA. Such design translates to more economical assays that are better suited for implementation in diagnostic laboratories.

Using our novel methodology, we aimed to characterize the dynamics of dscfDNA after LT and assess the utility of dscfDNA in diagnosing acute rejection after LT.

MATERIALS AND METHODS
=====================

Ethics
------

Ethical approval for this study was obtained from the Austin Health Human Research Ethics Committee (reference number: HREC/15/Austin/142) and Donate Life Australia (project number: 2015\#04). Ethical approval for the use of control normal blood samples was obtained from the Australian Red Cross Blood Service (agreement number: 15-06VIC-07).

Cohort A: Longitudinal Monitoring of dscfDNA After LT
-----------------------------------------------------

The longitudinal cohort was prospectively recruited at the Liver Transplant Unit of Victoria at Austin Health between June 2015 and Dec 2016 (Figure [1](#F1){ref-type="fig"}). Twenty recipients who underwent LT (under the donation after brain death pathway) were recruited. Informed consent was obtained upon recruitment.

![Outline of the study comprising a longitudinal cohort of 20 recipients (cohort A) and a cross-sectional cohort of 20 recipients (cohort B). LT, liver transplantation; tBPAR, treated biopsy-proven acute rejection.](txd-5-e462-g001){#F1}

LT was performed according to the institutional protocols. The management of the recipients undergoing LT was directed by a team of experienced transplant clinicians. Routine immunosuppression comprised a tapering regime of steroids, an antimetabolite (azathioprine or mycophenolate mofetil), and a calcineurin inhibitor (tacrolimus or cyclosporine).

Liver biopsies were performed following a clinical need to do so, as protocol biopsies are not performed at our institution. Blood tests such as full blood examination, urea electrolytes and creatinine, liver function tests (LFTs), and serum tacrolimus levels were performed on a regular basis to monitor the clinical course. Recipients were closely followed up with routine blood tests at outpatients following discharge, and blood tests were performed upon their outpatient visits.

In addition to the routine blood tests, an additional 15 mL of blood was sampled for dscfDNA analysis 24 hours before transplantation and on posttransplant days 3, 7, 14, 28, and 42. Fifteen milliliters of blood from the corresponding organ donor was also sampled before the organ procurement procedure by the organ procurement team.

In this specific cohort, the recipients were categorized into 3 groups: (1) uneventful, (2) treated biopsy-proven acute rejection (tBPAR), or (3) cholestasis. The uneventful group comprised recipients who underwent LT without complications. In this group, each recipient demonstrated typical and expected improvements in LFTs. As our institution does not perform protocol biopsies, recipients in this group did not undergo a liver biopsy after LT.

Recipients with persistent or atypical elevations in LFTs all underwent liver biopsies to determine a cause for the abnormality, and the recipients were classified into 2 further groups. The tBPAR group comprised recipients with acute cellular rejection (confirmed by a transplant pathologist) that was successfully treated by the modification of their immunosuppression therapy (pulsed steroids or modification of maintenance therapy). The cholestasis group comprised recipients with abnormal cholestatic LFTs and histopathology findings that did not require antirejection therapy.

Cohort B: Cross-sectional Evaluation of Diagnostic Accuracy of dscfDNA for tBPAR
--------------------------------------------------------------------------------

The cross-sectional cohort was recruited at the Liver Transplant Unit of Victoria between June 2016 and July 2017 (Figure [1](#F1){ref-type="fig"}). Four clinically stable recipients (\>1-y post-LT) who did not develop any posttransplant complications with normal LFTs were identified by the transplant clinicians from the Liver Transplant Unit of Victoria database. The 4 recipients were recruited, and 15 mL of blood was drawn for dscfDNA analysis.

Sixteen recipients (\>1-mo posttransplant) who were undergoing liver biopsies to investigate the cause for deteriorating LFTs (unexplained rising transaminases and cholestatic parameters) were recruited. A sample of blood (15 mL) was drawn from each recipient up to 3 hours before the liver biopsy procedure. In this cohort, the primary outcome was defined as tBPAR. Therefore, only the recipients who were treated (by pulsed steroids or adjustment of maintenance immunosuppression) for the episode of biopsy-proven acute rejection (acute cellular rejection confirmed by a pathologist) were classified as a positive event.

Archived pretransplant serum samples of the recipients and their corresponding organ donors were retrieved from −80°C storage for genotyping purposes (detailed below).

Quantification of dscfDNA
-------------------------

Blood processing and quantification of dscfDNA were performed according to our previously published protocols.^[@R25],[@R31]^ A schematic of the methodology is summarized in **Figure S1, SDC**, <http://links.lww.com/TXD/A212>.

All blood samples designated for dscfDNA analysis were collected using VACUETTE potassium-EDTA blood collection tubes (Greiner Bio-One International). The samples were processed within 3 hours of collection. Each blood sample was initially centrifuged at 800*g* for 10 minutes. The plasma fraction of the blood sample was transferred into a collection tube for a second centrifugation step at 1600*g* for 10 minutes. Subsequently, the plasma was aspirated and transferred into cryovials for storage at −80°C.

In the first step, each recipient and corresponding donor were genotyped using a panel of 9 DIPs. DNA was first extracted from the pretransplant buffy-coat (cohort A: organ donor and recipients) and pretransplant serum (cohort B: organ donor and recipients) using the QIAamp DNA Mini Kit (Qiagen) and QIAamp Circulating Nucleic Acid Kit (Qiagen), respectively.

Genotyping was subsequently performed by high-resolution melting analysis. A DIP was considered informative if an allele (deletion or insertion) was present in the donor and absent in the recipient. This step was performed only once for each recipient and organ donor pair.

The second step measured dscfDNA. DNA was first extracted from 4 mL of plasma derived from recipient blood samples using the QIAamp Circulating Nucleic Acid Kit (Qiagen). Probe-free assays that only amplified the respective informative donor-specific alleles were selected according to the genotyping information obtained in the first step. dscfDNA was measured using the plasma DNA extracted from the recipient blood samples on the Bio-Rad QX200 ddPCR platform (Bio-Rad Laboratories).

dscfDNA levels for each blood sample were calculated and presented as copies/mL of recipient plasma or copies/mL. All dscfDNA measurements were analyzed in batches. The dscfDNA results did not influence the management of the recipients.

Statistical Analysis
--------------------

Means and SDs were presented for normally distributed continuous variables. Median and interquartile ranges were presented for nonnormally distributed continuous variables. Where appropriate, the Student *t* test and ANOVA were used for parametric testing, and the Mann-Whitney *U* test and Kruskal-Wallis test were used for nonparametric analysis.

Diagnostic sensitivity and specificity were determined using receiver operating characteristics analysis. The area under the curve was used to compare the diagnostic accuracy of dscfDNA and LFTs. The Youden index was used to calculate optimal cutoffs. Statistical analyses were performed using SPSS Statistics v24 for MAC (IBM Corporation).

RESULTS
=======

Cohort A: Longitudinal Monitoring of dscfDNA After LT
-----------------------------------------------------

The average recipient age was 57.5 ± 8.6 years. The majority of the recipients were males. The common causes for LT are outlined in Table [1](#T1){ref-type="table"}. The average model for end-stage liver disease (MELD) score for this cohort of recipients was 18 ± 7. Forty percent had an underlying hepatocellular carcinoma before transplantation. The average organ donor age was 48 ± 15 years. There were more female than male organ donors. The causes of death before organ donation are listed in Table [1](#T1){ref-type="table"}. Three of the 20 recipients received a split LT (3/4 of the donor liver). The average donor risk index of the organ donor was 1.6 ± 0.3.

###### 

Clinical variables of the longitudinal cohort (cohort A)

![](txd-5-e462-g002)

The average age of transplantation of the recipient was 55.5 ± 8.6 years. The average operative time was 423 ± 71 minutes. The cold and warm ischemic times were 360 ± 84 and 43 ± 6 minutes, respectively. The average maximum alanine aminotransferase (ALT) was 1243 ± 1091 U/L. The average length of stay (LOS) was 15 ± 8 days, and the intensive care unit (ICU) LOS was 3 ± 2 days.

There were no significant differences between the clinical variables of the 3 subgroups. In this cohort, dscfDNA was analyzed on a total of 119 blood samples (derived from the 20 recipients across 6 time points). Due to logistical reasons, one of the recipients in the uneventful subgroup missed an episode of blood sampling at day 28.

Exponential Decline of dscfDNA After LT Reflected Uneventful Recovery
---------------------------------------------------------------------

All 14 recipients who underwent LT without any complications (uneventful subgroup) demonstrated stereotypic decline in dscfDNA. dscfDNA levels were higher in the earlier phases (days 3 and 7) after LT compared with the later phases (days 14, 28, and 42) (Figure [2](#F2){ref-type="fig"}).

![Donor-specific cell-free DNA (dscfDNA) dynamics over time of the 14 recipients who underwent liver transplantation without any complications. A decline in dscfDNA over time was indicative of successful implantation.](txd-5-e462-g003){#F2}

Median dscfDNA at days 3 and 7 was 1936 copies/mL (interquartile range \[IQR\], 1067--2658 copies/mL) and 1015 copies/mL (IQR, 363--1125 copies/mL), respectively. dscfDNA continued declining at day 14 with a median dscfDNA of 247 copies/mL (IQR, 153--358 copies/mL). dscfDNA plateaued at low median levels of 90 copies/mL (IQR, 67--241 copies/mL) at day 28 and 66 copies/mL (IQR, 50--105 copies/mL) at day 42.

dscfDNA Was Elevated in tBPAR and Was Independent of Cholestasis
----------------------------------------------------------------

Three recipients in the longitudinal cohort developed biopsy-proven acute rejection that required treatment (clinical progress summarized in Table [2](#T2){ref-type="table"}). dscfDNA was higher, compared with the median of the uneventful subgroup, in all 3 of the recipients on the day when the episode of biopsy-proven acute rejection was diagnosed and subsequently treated (Figure [3](#F3){ref-type="fig"}). Following treatment, dscfDNA decreased toward the median of the uneventful subgroup.

###### 

Serial monitoring of dscfDNA of the longitudinal cohort (cohort A)

![](txd-5-e462-g004)

![Donor-specific cell-free DNA (dscfDNA) was higher in the 3 recipients with treated biopsy-proven acute rejection when compared with the median dscfDNA of recipients who underwent liver transplantation without any complications. Improving dscfDNA reflects the successful treatment of acute rejection. The arrow with solid line denotes the day when the episode of biopsy-proven acute rejection was diagnosed and treated. Recipient 1: ▴, recipient 2: ◼, recipient 3: • and median of the uneventful recipients: ♦.](txd-5-e462-g005){#F3}

Three other recipients in the longitudinal cohort were diagnosed with cholestatic pathologies that were associated with notably abnormal cholestatic LFTs. Two were conservatively managed, and one required surgical reconstruction of the biliary anastomosis (Table [2](#T2){ref-type="table"}). dscfDNA in all 3 of these recipients was within the median of the uneventful group (Figure [4](#F4){ref-type="fig"}).

![Donor-specific cell-free DNA (dscfDNA) of the 3 recipients in the cholestasis subgroup was similar to the median dscfDNA of the recipients who underwent liver transplantation without any complications. Arrow with broken line denotes the day when the recipient underwent a liver biopsy, and the diagnosis of cholestasis was made. Recipient 1: ▴, recipient 2: ◼, recipient 3: • and median of the uneventful recipients: ♦.](txd-5-e462-g006){#F4}

Overall, the recipients with tBPAR demonstrated distinctively higher dscfDNA compared with the uneventful subgroup and cholestasis subgroup (**Figure S2, SDC**, <http://links.lww.com/TXD/A212>, and **Table S1, SDC**, <http://links.lww.com/TXD/A212>).

Notably, LFTs showed greater overlap between the subgroups (**Figure S2, SDC**, <http://links.lww.com/TXD/A212>). ALT and bilirubin did not differentiate the 3 different subgroups (**Table S1, SDC**, <http://links.lww.com/TXD/A212>). Alkaline phosphatase (ALP; at days 7, 14, and 28) and gamma-glutamyl transferase (GGT; at days 7 and 14) differentiated the uneventful subgroup from recipients with cholestasis but did not differentiate between recipients with cholestasis or tBPAR (**Table S1, SDC**, <http://links.lww.com/TXD/A212>).

Cohort B: Cross-sectional Evaluation of Diagnostic Accuracy of dscfDNA for tBPAR
--------------------------------------------------------------------------------

The average recipient age was 55.3 ± 12 years (Table [3](#T3){ref-type="table"}). The causes leading to LT were similar to that of cohort A. The MELD score was 22 ± 7. Almost 50% of the cohort had an underlying hepatocellular carcinoma before transplantation. The average organ donor age was 42 ± 17 years. Eighteen of the recipients received grafts from donation after brain death organ donors, and 2 of the recipients received grafts from organ donors after circulatory death. One of the recipients received a split LT. The average donor risk index was 1.5 ± 0.4.

###### 

Clinical variables of the cross-sectional cohort (cohort B)

![](txd-5-e462-g007)

The average age of transplantation of the recipient was 50.1 ± 11.6 years. The average operative time was 477 ± 118 minutes. The cold and warm ischemic times were 398 ± 99 and 42 ± 7 minutes, respectively. The average maximum ALT was 1266 ± 1963 U/L. The average LOS was 15 ± 8 days, and the ICU LOS was 3 ± 2 days. The duration from LT to biopsy was 1641 ± 1357 days.

No significant differences were identified among the clinical variables of the 3 subgroups. In this cohort, dscfDNA was analyzed on 20 blood samples (1 sample/recipient) (Figure [5](#F5){ref-type="fig"}).

![Cross-sectional analysis of donor-specific cell-free DNA (dscfDNA) of 14 clinically stable recipients at day 42 after liver transplant (LT) from cohort A (light gray), 4 clinically stable recipients at least 1 y after LT from cohort B (dark gray), 10 recipients without treated biopsy-proven acute rejection (tBPAR) from cohort B (zig-zag pattern), and 6 recipients with tBPAR from cohort B (stripe pattern). Dotted line represents the optimal threshold for discriminating recipients with tBPAR from those without tBPAR or those who were clinically stable.](txd-5-e462-g008){#F5}

dscfDNA Identified tBPAR With Superior Performance Compared With LFTs
---------------------------------------------------------------------

Posttransplant recipients may present at the outpatient clinic with abnormal LFTs that require further investigations. These include imaging, endoscopy, or liver biopsies. We assessed the value of dscfDNA in discriminating recipients with abnormal LFTs and tBPAR (n = 6) from the recipients with abnormal LFTs and without tBPAR (n = 10) in this context. The findings showed that higher dscfDNA was significantly associated with tBPAR (**Figure S3, SDC**, <http://links.lww.com/TXD/A212>). On the other hand, ALT, ALP, GGT, and bilirubin were not indicative of tBPAR (**Figure S3, SDC**, <http://links.lww.com/TXD/A212>).

Among the recipients who underwent liver biopsies, dscfDNA accurately identified recipients with tBPAR and recipients without tBPAR (Table [4](#T4){ref-type="table"}; **Figure S4, SDC**, <http://links.lww.com/TXD/A212>). The diagnostic performance based on the area under the curve of dscfDNA (96.7%; confidence interval \[CI\], 88.5%-100%) was superior to ALT (64.2%; CI, 31.5-96.8), ALP (48.3%; CI, 15.0%-81.6%), GGT (55.8%; CI, 24.9%-86.8%), and bilirubin (38.3%; CI, 9.5%-67.1%). At a threshold of 898 copies/mL, dscfDNA had a clinical sensitivity of 83.3% (CI, 35.9%-99.6%) and clinical specificity of 100% (87.7%--100%).

###### 

ROC analysis of the recipients with tBPAR (n = 6) when compared with those without tBPAR (n = 10)

![](txd-5-e462-g009)

The analysis was extended to determine the value of dscfDNA in discriminating recipients with tBPAR (n = 6) from a group which included both patients without tBPAR and those who were clinically well (n = 28 total) with normal LFTs. dscfDNA, ALT, and GGT were significantly higher in recipients with tBPAR, when compared with those recipients without tBPAR and those who were clinically well (**Figure S3, SDC**, <http://links.lww.com/TXD/A212>).

Receiver operating characteristics analysis demonstrated that dscfDNA was superior to LFTs in discriminating recipients with tBPAR from those without tBPAR and those who were clinically well (Table [5](#T5){ref-type="table"}; **Figure S5, SDC**, <http://links.lww.com/TXD/A212>). At a threshold of 898 copies/mL, dscfDNA had a clinical sensitivity of 83.3% (CI, 35.9%-99.6%) and clinical specificity of 100% (87.7%--100%).

###### 

ROC analysis of the recipients with tBPAR (n = 6) when compared with those without tBPAR and those who were clinically well (n = 28)

![](txd-5-e462-g010)

Applying the dscfDNA Threshold for Surveillance of tBPAR Early After LT
-----------------------------------------------------------------------

The threshold of 898 copies/mL was applied to the longitudinal cohort (cohort A). Due to the high median dscfDNA of the uneventful subgroup at days 3 (1936 copies/mL) and 7 (1015 copies/mL), the diagnostic performance is of limited value. The threshold was most reliable from day 14 onward. Notably, from day 14 onward, all 3 of the recipients with cholestasis had dscfDNA that were below the tBPAR threshold of 898 copies/mL (Table [2](#T2){ref-type="table"}).

At day 14, all 3 of the recipients with tBPAR had dscfDNA levels that were above the threshold (Table [2](#T2){ref-type="table"}). For recipients 1 and 2, dscfDNA was measured during the decay phase after the treatment for the episode of acute rejection was instituted. Recipient 1 was diagnosed with tBPAR on day 7. One week after the treatment, the dscfDNA was 952 copies/mL. Although the dscfDNA was marginally above the threshold, the levels continued to decline below the threshold at subsequent time points after successful treatment. Recipient 2 was diagnosed with tBPAR on day 9. Five days after the treatment, the dscfDNA remained at markedly elevated levels of 1821 copies/mL. The levels continued to decline below the threshold after successful treatment. Recipient 3 was diagnosed with tBPAR on day 14. For this recipient, dscfDNA was markedly elevated at 10 769 copies/mL and then declined below the threshold after successful treatment at subsequent time points.

DISCUSSION
==========

There is a clinical need for accurate blood-based tests to diagnose acute rejection after solid-organ transplantation. Several large studies have established the clinical utility of dscfDNA for acute rejection after heart, lung, and kidney transplantation.^[@R10]-[@R12],[@R24],[@R32],[@R33]^ Reports pertaining to the role of dscfDNA in LT remain limited. At the time of writing, only a few small studies (≤17 recipients)^[@R16],[@R19],[@R25],[@R34]^ and one large prospective study (115 recipients) have been published to date^[@R13]^.

In this study, we demonstrated that dscfDNA was indicative of acute rejection after LT. Uncomplicated clinical progress was associated with a stereotypic decrease in dscfDNA (Figure [2](#F2){ref-type="fig"}). Furthermore, serial monitoring of dscfDNA identified the recipients with tBPAR and facilitated the assessment of response to antirejection therapy (Figure [3](#F3){ref-type="fig"}). Importantly, we also showed that dscfDNA was superior to LFTs in identifying recipients with tBPAR (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}).

Our findings were consistent with previous dscfDNA studies in LT^[@R13],[@R16],[@R19],[@R25],[@R34]^ and independently affirmed that dscfDNA is of clinical value for acute rejection after LT. There were, however, 2 key aspects of our study that differed to the other published studies.

First, the more clinically relevant endpoint of tBPAR was adopted. Mild histological rejection is often not treated, and maintenance immunosuppression is not modified.^[@R35],[@R36]^ Many recipients with mild rejection will improve spontaneously without adverse clinical outcomes. To evaluate the value of dscfDNA in identifying clinically relevant episodes of acute rejection that required treatment, the endpoint of tBPAR (a standard in high-quality LT trials^[@R37]-[@R39]^) was thus employed in our study.

Second, unlike majority of the other published methodologies,^[@R19],[@R20],[@R22]^ our ddPCR methodology measured dscfDNA by absolute quantification (ie, copies/mL of dscfDNA) as compared to relative abundance (ie, percentage of dscfDNA: donor-specific DNA divided by the sum of donor-specific and recipient-specific DNA).

Measurement by relative abundance internally controls for sample processing variables (ie, DNA extraction yields). The disadvantage in doing so is that numerous factors such as exercise,^[@R40]^ infection,^[@R16]^ poor collection techniques,^[@R41]^ and poor sample processing^[@R42]^ increase recipient-specific DNA. These factors can confound relative abundance measurements and hence reduce the clinical sensitivity of detecting an event. Absolute quantification of donor alleles was thus adopted in this study to maximize clinical sensitivity. Attributed to this difference, direct comparison of healthy dscfDNA threshold (ie, 10% with the study by Schütz et al^[@R13]^) was not possible.

Despite the disparities in study endpoint and assay methodologies, our results supported the notion that the performance of dscfDNA is superior to LFTs in diagnosing recipients with acute rejection. This finding is readily explained by the unique and inherent physiology of dscfDNA.^[@R11],[@R13]^ Because each cell has 2 haploid copies of the genome, the death of a cell derived from the donor organ will release 2 haploid copies of the donor-specific genome into the blood circulation. The amount of donor-specific DNA that is quantifiable in the plasma directly correlates to the degree of cell death that occurs during acute rejection.

On the other hand, LFTs are intrinsically different. The levels of bilirubin, ALP, GGT, and ALP are highly dependent on complex cellular interactions of transcriptional activity, translational processes, biochemical modifications, clearance, membrane permeability, and enzymatic leakage. These factors hence limit both the sensitivity and specificity of LFTs.

On the basis of our reported findings, we considered that dscfDNA may improve several aspects of clinical management after LT. First and foremost, dscfDNA could be used as a liquid biopsy for the surveillance of tBPAR in recipients after LT. In recipients with dscfDNA that surpass the threshold (ie, \>898 copies/mL), antirejection therapy may be instituted. The size of our study precluded the formal assessment of the relationship between dscfDNA, rejection severity, and the type of antirejection therapy that was required to treat the rejection episode. Larger multicenter studies are necessary to further evaluate and refine the diagnostic and treatment thresholds of dscfDNA.

Second, dscfDNA could be used to guide investigational decisions early (ie, within the first 2 wk) after LT. Numerous perioperative variable such as donor organ quality, ischemic reperfusion injury, ischemic times, and transfusion of blood products could increase dscfDNA.^[@R43],[@R44]^ These factors compromise and limit the clinical utility of dscfDNA to diagnose tBPAR. However, we considered that the serial monitoring of dscfDNA within the first 2 weeks after LT may be useful to determine the choice of further diagnostic tests when investigating recipients with abnormal cholestatic LFTs (a common finding early after LT).

For instance, the clinician may opt to perform a liver biopsy to confirm acute rejection in a recipient with abnormal cholestatic LFTs and abnormal dscfDNA (ie, twice the median of the uneventful subgroup). In a separate clinical scenario, the clinician may elect to watch and wait and not perform a liver biopsy in a recipient with abnormal cholestatic LFTs and normal dscfDNA. The analysis of dscfDNA could, hence, be used to determine the group of recipients who may benefit the most from undergoing tissue biopsies.

Third, serial monitoring of dscfDNA could complement LFTs in monitoring antirejection therapy response following the diagnosis and treatment of acute rejection. Consistent with studies in both liver and other types of solid-organ transplantation,^[@R10],[@R11],[@R13]^ dscfDNA normalized with successful treatment of acute rejection (Figure [3](#F3){ref-type="fig"}). Serial monitoring of dscfDNA has particular relevance in those patients where LFTs are slow to normalize after commencement of treatment of acute rejection. It may obviate the need for repeat liver biopsies to assess response. Owing to the intrinsic characteristics of dscfDNA, close monitoring of dscfDNA in conjunction to LFTs may offer valuable information pertaining to both graft integrity and treatment responses.

We recognize that our study has several limitations. The sample size is small, and this precluded formal multivariate analyses. Nevertheless, we considered that this sample size was sufficient to demonstrate the clinical utility of dscfDNA and also test the feasibility of our novel methodology to effectively measure dscfDNA within a clinically relevant turnaround time. Although only 40 recipients were presented, this is the second largest dscfDNA study in LT at the time of writing to reinforce the clinical value of dscfDNA in LT.

Importantly, protocol biopsies were not performed in our study to correlate dscfDNA with histopathological outcomes. While protocol biopsies may identify recipients with subclinical rejection, the risks (ie, pain, bleeding, infection) outweighed the benefits (ie, identifying clinically significant outcomes that require treatment). Similar to mild rejection, subclinical rejection may spontaneously improve without further treatment, and this suggests that, if truly present, the episode of rejection would have negligible impact on clinical outcomes. The use of biopsy-proven acute rejection requiring treatment (tBPAR) as an endpoint, as discussed above, was considered to address this limitation.

In conclusion, our findings support the recent study showing that dscfDNA provides an independent clinical value for sensitive detection of acute rejection after LT.^[@R13]^ Herein, we used a highly feasible and readily performed probe-free ddPCR methodology with clinically relevant turnaround times to measure dscfDNA in 2 separate cohorts of recipients after LT. Despite differences in endpoint and assay platforms, our findings provide more evidence supporting the value of dscfDNA for acute rejection in LT.
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